MX2023009006A - Fracciones que prolongan la semivida y metodos de uso de estas. - Google Patents
Fracciones que prolongan la semivida y metodos de uso de estas.Info
- Publication number
- MX2023009006A MX2023009006A MX2023009006A MX2023009006A MX2023009006A MX 2023009006 A MX2023009006 A MX 2023009006A MX 2023009006 A MX2023009006 A MX 2023009006A MX 2023009006 A MX2023009006 A MX 2023009006A MX 2023009006 A MX2023009006 A MX 2023009006A
- Authority
- MX
- Mexico
- Prior art keywords
- extending moieties
- same
- tâ1⁄2
- methods
- life extending
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1883—Neuregulins, e.g.. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2013—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2221—Relaxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5434—IL-12
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Toxicology (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Superconductors And Manufacturing Methods Therefor (AREA)
- Epoxy Compounds (AREA)
- Steroid Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163144696P | 2021-02-02 | 2021-02-02 | |
| PCT/US2022/014728 WO2022169757A1 (en) | 2021-02-02 | 2022-02-01 | Half-life extending moieties and methods of using the same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023009006A true MX2023009006A (es) | 2023-08-08 |
Family
ID=80735776
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023009006A MX2023009006A (es) | 2021-02-02 | 2022-02-01 | Fracciones que prolongan la semivida y metodos de uso de estas. |
Country Status (18)
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20260109751A1 (en) * | 2022-12-30 | 2026-04-23 | Eli Lilly And Company | Methods of dulaglutide purification using hydrophobic interaction chromatography |
| EP4731669A2 (en) * | 2023-06-21 | 2026-04-29 | Eli Lilly and Company | Compounds for the delivery of granulin across the blood brain barrier |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2259802A1 (en) * | 2008-03-31 | 2010-12-15 | Glaxo Group Limited | Drug fusions and conjugates |
| AU2012280474A1 (en) * | 2011-07-01 | 2014-01-16 | Bayer Intellectual Property Gmbh | Relaxin fusion polypeptides and uses thereof |
| AU2015231170B2 (en) * | 2014-03-20 | 2019-10-03 | Bristol-Myers Squibb Company | Serum albumin-binding fibronectin type III domains |
| WO2018104444A1 (en) * | 2016-12-07 | 2018-06-14 | Ablynx Nv | Improved serum albumin binding immunoglobulin single variable domains |
| EP3807311A4 (en) * | 2018-04-24 | 2022-01-26 | National Research Council of Canada | SERUM ALBUM BINDING ANTIBODIES FOR TUNABLE HALF-LIFE OF BIOLOGICALS |
| TWI844709B (zh) * | 2019-07-31 | 2024-06-11 | 美商美國禮來大藥廠 | 鬆弛素(relaxin)類似物及其使用方法 |
-
2022
- 2022-02-01 JP JP2023546450A patent/JP2024506145A/ja active Pending
- 2022-02-01 CA CA3204225A patent/CA3204225A1/en active Pending
- 2022-02-01 KR KR1020237025927A patent/KR20230137342A/ko active Pending
- 2022-02-01 EP EP22709849.8A patent/EP4288452A1/en active Pending
- 2022-02-01 US US18/259,500 patent/US20240316154A1/en active Pending
- 2022-02-01 MX MX2023009006A patent/MX2023009006A/es unknown
- 2022-02-01 WO PCT/US2022/014728 patent/WO2022169757A1/en not_active Ceased
- 2022-02-01 AU AU2022217754A patent/AU2022217754A1/en active Pending
- 2022-02-01 CN CN202280012629.0A patent/CN116802209A/zh active Pending
- 2022-02-01 CR CR20230366A patent/CR20230366A/es unknown
- 2022-02-01 PE PE2023002220A patent/PE20240233A1/es unknown
-
2023
- 2023-06-30 ZA ZA2023/06754A patent/ZA202306754B/en unknown
- 2023-07-03 IL IL304219A patent/IL304219A/en unknown
- 2023-07-27 DO DO2023000149A patent/DOP2023000149A/es unknown
- 2023-07-27 CO CONC2023/0010002A patent/CO2023010002A2/es unknown
- 2023-07-30 JO JOJO/P/2023/0173A patent/JOP20230173A1/ar unknown
- 2023-08-01 EC ECSENADI202358246A patent/ECSP23058246A/es unknown
- 2023-08-02 CL CL2023002285A patent/CL2023002285A1/es unknown
-
2025
- 2025-10-02 CL CL2025003008A patent/CL2025003008A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PE20240233A1 (es) | 2024-02-16 |
| ECSP23058246A (es) | 2023-09-29 |
| CO2023010002A2 (es) | 2023-09-08 |
| JP2024506145A (ja) | 2024-02-09 |
| KR20230137342A (ko) | 2023-10-04 |
| CR20230366A (es) | 2023-10-03 |
| CN116802209A (zh) | 2023-09-22 |
| ZA202306754B (en) | 2025-02-26 |
| JOP20230173A1 (ar) | 2023-07-30 |
| CL2023002285A1 (es) | 2024-02-23 |
| AU2022217754A1 (en) | 2023-07-27 |
| DOP2023000149A (es) | 2023-09-15 |
| CA3204225A1 (en) | 2022-08-11 |
| EP4288452A1 (en) | 2023-12-13 |
| WO2022169757A1 (en) | 2022-08-11 |
| CL2025003008A1 (es) | 2025-12-19 |
| US20240316154A1 (en) | 2024-09-26 |
| IL304219A (en) | 2023-09-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2024014142A (es) | Novedosos inhibidores de molecula peque?a de factores de transcripcion tead | |
| PH12022552739A1 (en) | Fused tricyclic kras inhibitors | |
| ZA202002094B (en) | Trispecific proteins and methods of use | |
| NZ754051A (en) | Novel antibodies and uses thereof | |
| MX2026002469A (es) | Nuevas moleculas de acido nucleico artificiales | |
| JOP20200277B1 (ar) | مركبات تثبيط rip1 وطرق لتحضير واستخدامها | |
| PH12019501350A1 (en) | Amino-triazolopyridine compounds and their use in treating cancer | |
| EP4026835A3 (en) | Pd-1/pd-l1 inhibitors | |
| TN2015000174A1 (en) | Pyrrolopyrimidine compounds as kinase inhibitors | |
| MD20150035A2 (ro) | Inhibitori de tirozinkinaza Bruton | |
| TW200745103A (en) | Substituted 7-azaindazoles, compositions containing them, production process and use | |
| CA2871471C (en) | Dna-pk inhibitors | |
| MX382562B (es) | Derivados pirrolidina espiro-condensados como inhibidores de enzimas desubiquitinantes (dub). | |
| EP1888066A4 (en) | AMINOCYCLOHEXANE AS DIPEPTIDYLPEPTIDASE IV HEMMER FOR TREATMENT OR PREVENTION OF DIABETES | |
| ZA202306754B (en) | Half-life extending moieties and methods of using the same | |
| PH12014501815A1 (en) | Purinone compounds as kinase inhibitors | |
| EA201101650A1 (ru) | Новые производные пиримидина и их применение в лечении злокачественных новообразований и последующих заболеваний | |
| PH12013501089A1 (en) | Pyrimidinone compounds for use in the treatment of diseases or conditions mediated by lp - pla2 | |
| EP1951729A4 (en) | OXYGEN-BOUND PYRIMIDINE DERIVATIVES | |
| JO2870B1 (en) | Amino Tetra Hydro Pirans as Inhibitors of Peptide Dipeptide IV for the Treatment or Prevention of Diabetes | |
| IN2012DN00721A (cg-RX-API-DMAC10.html) | ||
| MX2022012471A (es) | Combinaciones de inhibidores de menina e inhibidores de cyp3a4 y métodos de uso de las mismas. | |
| EA201790818A1 (ru) | 2-амино-6-(дифторметил)-5,5-дифтор-6-фенил-3,4,5,6-тетрагидропиридины как ингибиторы bace1 | |
| PH12021551304A1 (en) | Tyrosine kinase inhibitors, compositions and methods there of | |
| MX2023010711A (es) | Fenalquilaminas y métodos de preparación y uso de las mismas. |